J Thorac Oncol. 2015 Dec 24. pii: S1556-0864(15)00255-5. doi: 10.1016/j.jtho.2015.12.102. [Epub ahead of print]
- Response to crizotinib observed in lung adenocarcinoma with MET copy number gain but without high-level MET/CEP7 ratio, MET overexpression or exon 14 splicing mutations.
Zhang Yan, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2015 12 (From HuGE Literature Finder)
Response to crizotinib observed in lung adenocarcinoma with MET copy number gain but without high-level MET/CEP7 ratio, MET overexpression or exon 14 splicing mutations.
Abstract
Copyright © 2015 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
KEYWORDS:
MET/CEP7 ratio; Mesenchymal-epithelial transition; copy number gain; crizotinib; lung cancer
- PMID:
- 26724472
- [PubMed - as supplied by publisher]
No hay comentarios:
Publicar un comentario